Diabetic neuropathy, also known as diabetes-induced nerve damage, is a common complication of diabetes and occurs when high blood glucose levels damage nerves throughout the body. Diabetic neuropathy is associated with symptoms of pain, numbness and loss of sensation in extremities such as the hands and feet. Worldwide, diabetic neuropathy is estimated to impact more than 50% of the diabetic population, thereby limiting the daily functioning and contributing to decreased quality of life of people with diabetes. Due to its worldwide impact, it is crucial that the management of this condition is highly effective in order to minimize the devastating symptoms of this condition and maintain the health, functioning and well-being of the individuals with diabetes.
Logo Neuropad ist ein modernes Diagnosehilfsmittel. Mit Neuropad kann deren Nervenfunktion aufgebraucht sein schätzen. Der Funktionsprinzip dieses Gerätes besteht darin, daß das V ramp V skin der Fußsohlen nachzuweisen ist. Dazu auf der Neuropad Klotze ist ein spezielles Farbekh material vorgenannt, welches in Abhängigkeit von der gewarteten Haut Feuchtigkeit Farbunterschiede aufweist. Dieses Gerät bietet den großen Vorteil ohne großen Zeitverlust in der Praxis den Patienten zu testen. Als Ausfallhilfe kann Neuropad sicherlich auch in den häuslichen Ambianzen genutzt werden.
Diabetic neuropathy (DN) is a serious complication of diabetes that affects a large part of diabetic patients. Thus, early detection of DN is highly important. Our studies, as well as those of other research groups, like Ponirakis et al. (2014), have shown the potential of Neuropad for early detection of diabetic neuropathy with a high diagnostic accuracy compared to the other methods. Tsapas et al. (2014) have also confirmed the validity of Neuropad as a screening tool for early detection of diabetic neuropathy. Early detection of neuropathy has many benefits for the diabetic patient and improves the management of the diabetic condition. Early detection can prevent further neuropathy progression and improve the patient’s quality of life.
A further advantage is that Neuropad is affordable to apply in a doctor’s surgery. According to a 2020 study by Rodríguez-Sánchez et al. that specifically examined cost-effectiveness, Neuropad is economically favourable to the current testing standards. As such, it can reach a larger population, such as people from lower socio-economic circumstances who are not normally reached by other screening methods. Applying the simple Neuropad test in the clinical diagnostics of the healthcare sector opens up new opportunities for patient management, which in turn also increases patient involvement.
Although the new sensor is helpful for screening for neuropathy, there are a number of limitations that must be considered. For example, although the sensor is very useful for screening, a full clinical examination is still required to diagnose the presence of diabetic neuropathy. Other investigations may also be required. Another limitation of the sensor is that it is limited to detecting the changes in temperature and moisture that occur in the skin of people with neuropathy, and therefore does not measure other changes that may occur. It is therefore very important that patients receiving Neuropad undergo regular ongoing education and assessment.
In summary, Neuropad is a valuable tool to manage diabetic neuropathy due to its rapid diagnostic function and cost-effectiveness. With the focus on early detection and ease of use, Neuropad is an important tool to help patients with diabetic neuropathy to maintain a good quality of life. Neuropad is a tool that helps to manage diabetic neuropathy and it has several benefits that could improve patient outcomes and quality of life. The primary advantage of Neuropad is that it can lead to early diagnosis of the condition. The foot temperature test offered by Neuropad can indicate nerve damage in patients with diabetic neuropathy before any other symptoms show. Studies have shown that early diagnosis of the condition allows for quicker intervention through better management of the patient’s lifestyle and through treatment, which can delay the worsening of the disease (Yang et al. 2024; Goddard et al. 2020). With early diagnosis and quicker intervention, symptoms such as pain and numbness in the feet may be reduced, allowing patients to be more active (Liu 2018).
Using the Neuropad can also be a simple process. As a result, more assessments can be carried out from home on a regular basis. Thus, patients have more control over the management of their condition. With more regular monitoring of their foot condition, patients may be more vigilant to other aspects of foot care, which will also serve to help prevent conditions such as ulcers and infection from developing.
In spite of the advantages mentioned, the use of Neuropad has its own limitations. One of the major constraints is the dependency on the clinical situation in which Neuropad is used. In the case of patients with altered foot temperature and blood flow due to reasons other than neuropathy, the diagnostic accuracy of Neuropad cannot be guaranteed. Thus, this method may not work efficiently in case of different types of neuropathies or circulatory disturbances. Furthermore, the efficacy of the device needs to be confirmed through more reliable and robust studies, so as to enable its applicability in a wider range of clinical situations (Zografou et al. 2020; Yoshioka & Okada, 2012).
In order to verify the efficacy of Neuropad, comparative studies are necessary. Research carried out by Ponirakis et al. (2015) and Burgess et al. (2021) provides a basis for comparison with existing diagnostic procedures and consequently for verification of the Neuropad’s efficiency. Comparative studies can confirm whether the application of Neuropad contributes to the improvement of the diagnostic process and what its benefits are, in relation to existing methods. It will then be possible for healthcare professionals to decide when and how to integrate the use of Neuropad in the treatment of diabetic neuropathy.
In summary, it is satisfying to see a product like Neuropad which really can make a difference to the management of diabetic neuropathy and so potentially aid earlier diagnosis and more effective management of the condition for the benefit of the patient. However, it is also important that practitioners of all disciplines remember the limitations of the technology and acknowledge the need for further research. It is a matter of balancing the advantages and disadvantages of what is still a relatively new product and, with wise use, Neuropad could make a real contribution to further improvements in patient care and a better quality of life for patients with diabetic neuropathy.
Citations:
Rodríguez-Sánchez, B., Peña-Longobardo, L.M. and Sinclair, A.J., 2020. Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy: B. Rodríguez-Sánchez et al. The European Journal of Health Economics, 21(3), pp.335-349. https://link.springer.com/article/10.1007/s10198-019-01134-2
Yang, Z., Zhao, S., Lv, Y., Xiang, L., Zhang, X., Feng, Z., Liu, Z. and Li, R., 2024. A new quantitative neuropad for early diagnosis of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews, 40(8), p.e70010. https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.70010
Ponirakis, G., Petropoulos, I.N., Fadavi, H.A., Alam, U., Asghar, O., Marshall, A., Tavakoli, M. and Malik, R.A., 2014. The diagnostic accuracy of Neuropad® for assessing large and small fibre diabetic neuropathy. Diabetic medicine, 31(12), pp.1673-1680. https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.12536
Ponirakis, G., Fadavi, H., Petropoulos, I.N., Azmi, S., Ferdousi, M., Dabbah, M.A., Kheyami, A., Alam, U., Asghar, O., Marshall, A. and Tavakoli, M., 2015. Automated quantification of neuropad improves its diagnostic ability in patients with diabetic neuropathy. Journal of diabetes research, 2015(1), p.847854. https://onlinelibrary.wiley.com/doi/abs/10.1155/2015/847854
Tsapas, A., Liakos, A., Paschos, P., Karagiannis, T., Bekiari, E., Tentolouris, N. and Boura, P., 2014. A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis. Metabolism, 63(4), pp.584-592. https://www.sciencedirect.com/science/article/pii/S0026049513004137
Spallone, V., Morganti, R., Siampli, M., Fedele, T., D’Amato, C., Cacciotti, L. and Maiello, M.R., 2009. Neuropad as a diagnostic tool for diabetic autonomic and sensorimotor neuropathy. Diabetic medicine, 26(7), pp.686-692. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1464-5491.2009.02760.x
Goddard, K., Pennington, M., Kartha, M.R., Macmillan, T., Bunce, C., Summers, J.A., Keevil, S. and Chalkidou, A., 2020. Complex clinical pathways: assessing the value of a device for detecting diabetic peripheral neuropathy. The Diabetic Foot Journal, 23(1), pp.16-20. https://diabetesonthenet.com/wp-content/uploads/pdf/dotn073549c3deb3dae745491a69e4805b33.pdf
Burgess, J., Frank, B., Marshall, A., Khalil, R.S., Ponirakis, G., Petropoulos, I.N., Cuthbertson, D.J., Malik, R.A. and Alam, U., 2021. Early detection of diabetic peripheral neuropathy: a focus on small nerve fibres. Diagnostics, 11(2), p.165. https://www.mdpi.com/2075-4418/11/2/165
Yoshioka, K. and Okada, H., 2012. Useful application of the Neuropad test for assessment of diabetic polyneuropathy. Internal Medicine, 51(23), pp.3241-3245. https://www.jstage.jst.go.jp/article/internalmedicine/51/23/51_51.8366/_article/-char/ja/
Zografou, I., Iliadis, F., Sambanis, C. and Didangelos, T., 2020. Validation of neuropad in the assessment of peripheral diabetic neuropathy in patients with diabetes mellitus versus the Michigan neuropathy screening instrument, 10g monofilament application and biothesiometer measurement. Current Vascular Pharmacology, 18(5), pp.517-522. https://www.ingentaconnect.com/content/ben/cvp/2020/00000018/00000005/art00010
University lecturer, runner, cynic, researcher, skeptic, forum admin, woo basher, clinician, rabble-rouser, blogger, dad.
